Decrease in blood pressure and regression of cardiovascular complications by angiotensin II vaccine in mice.
Vaccines have been recently developed to treat various diseases such as cancer, rheumatoid arthritis and Alzheimer's disease in addition to infectious diseases. However, before use in the clinical setting, vaccines targeting self-antigens must be demonstrated to be effective and safe, evoking a...
Enregistré dans:
Auteurs principaux: | Futoshi Nakagami, Hiroshi Koriyama, Hironori Nakagami, Mariana Kiomy Osako, Munehisa Shimamura, Mariko Kyutoku, Takashi Miyake, Tomohiro Katsuya, Hiromi Rakugi, Ryuichi Morishita |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Public Library of Science (PLoS)
2013
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/cdcd8e024d3e4ac6869e79224ddf17f6 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
The CD153 vaccine is a senotherapeutic option for preventing the accumulation of senescent T cells in mice
par: Shota Yoshida, et autres
Publié: (2020) -
Development of anti-thrombotic vaccine against human S100A9 in rhesus monkey
par: Munehisa Shimamura, et autres
Publié: (2021) -
RAGE ligands stimulate angiotensin II type I receptor (AT1) via RAGE/AT1 complex on the cell membrane
par: Serina Yokoyama, et autres
Publié: (2021) -
Hepatocyte Growth Factor Prevented High-Fat Diet-Induced Obesity and Improved Insulin Resistance in Mice
par: Jun Muratsu, et autres
Publié: (2017) -
Essential role for miR-196a in brown adipogenesis of white fat progenitor cells.
par: Masaki Mori, et autres
Publié: (2012)